Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBLINGUALGeneric

KYNMOBI

APOMORPHINE HYDROCHLORIDE

Standard Dose
30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview KYNMOBI is listed in Drugs@FDA under application 210875 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient APOMORPHINE HYDROCHLORIDE Form and strength FILM;SUBLINGUAL - 30MG Sponsor SUMITOMO PHARMA AM Submission history Latest submission status date: 2022-09-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview KYNMOBI is listed in Drugs@FDA under application 210875 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient APOMORPHINE HYDROCHLORIDE Form and strength FILM;SUBLINGUAL - 30MG Sponsor SUMITOMO PHARMA AM Submission history Latest submission status date: 2022-09-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.